Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase NA 1Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Sarcoma 2Plasma cell 2Thoracic 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Melanoma 323Skin Neoplasms 164Carcinoma, Basal Cell 90Keratosis, Actinic 62Lymphoma, T-Cell, Cutaneous 60Breast Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Mycosis Fungoides 46Lymphoma, Non-Hodgkin 46Sezary Syndrome 44Lymphoma, Follicular 44Lymphoma, Large B-Cell, Diffuse 43Lymphoma, B-Cell, Marginal Zone 43Lymphoma, Mantle-Cell 42Burkitt Lymphoma 42Hodgkin Disease 41Carcinoma, Squamous Cell 41Lymphoma, Large-Cell, Immunoblastic 40Neoplasms 39Multiple Myeloma 39Lymphoma 39Leukemia, Myeloid, Acute 35Leukemia, Myeloid, Accelerated Phase 32Myeloproliferative Disorders 31Leukemia, Myeloid, Chronic-Phase 31Congenital Abnormalities 30Leukemia, Hairy Cell 29Sarcoma 28Primary Myelofibrosis 28

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Drug-Related Side Effects and Adverse Reactions × Dermatologic × Clear all
NCT05652673 2025-02-28

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Erasmus Medical Center

Phase NA Recruiting
80 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡